This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
NKE Beats Earnings, Spotify's Video Push, & AMZN's Big Pharma Purchase
by Madeleine Johnson
On today's episode of the Zacks Friday Finish Line, Editor Maddy Johnson is joined by Ben Rains, an Associate Stock Strategist here at Zacks, to take on this week's biggest stories, including Nike's latest quarterly earnings results, Spotify's media ambitions, and Amazon's latest assault on the healthcare industry.
After a Historic Rise, Should You Still Buy Amazon (AMZN) Stock?
by Afrasiab Mian
With massive growth already baked into its stock price, many investors may feel that Amazon stock is too expensive and that they have missed their chance to cash in. Is this truly the case? Let's take a look.
Investors Shouldn't Panic About Amazon's PillPack Purchase
by Benjamin Rains
Shares of pharmacy giants CVS (CVS), Rite Aid (RAD), and Walgreens Boots Alliance (WBA) all plummeted on Thursday morning after Amazon (AZMN) announced its purchase of online pharmacy delivery startup PillPack. The move clearly has some investors worried that Amazon's push into the pharmaceutical industry will hurt the current powers. So let's take a look at more of the details to find out what's really going on.
Want to Tap Merger Mania? Play Top-Ranked Health Care ETFs
by Sanghamitra Saha
What is driving Healthcare merger-mania and how to tap it with ETFs.
Rite Aid-Albertsons Deal: US SEC Sanctions Proxy Materials
by Zacks Equity Research
Rite Aid (RAD) is moving closer to completing its previously announced merger with Albertsons. The company's shareholders are going to cast their votes regarding the deal on Aug 9.
Should You Buy Grocery Stocks, WMT, COST, TGT, After Kroger's Strong Quarter?
by Benjamin Rains
Shares of Kroger (KR) surged over 10% on Thursday to inch near their 52-week high after the company posted better-than-expected quarterly results. Investors were also likely pleased to see that the grocery chain's e-commerce initiatives started to pay off. The question is should investors think about buying grocery stocks as Amazon-based (AMZN) fears seem to have been overblown.
Walgreens-GE Faceoff: How Impactful is it for Dow Investors?
by Urmimala Biswas
The stock performance of Walgreens Boots (WBA) currently does not offer much conviction. Over the past year, shares show a decline of 17.9%.
Humana, Walgreens Team Up to Provide Better Senior Care
by Zacks Equity Research
Humana (HUM) ties up with Walgreens to provide better primary care and other services to seniors of the Kansas City Community.
Anthem Boosts Integrated Care With Aspire Health Buyout
by Zacks Equity Research
Anthem's (ANTM) acquisition of Aspire Health points to its increased efforts in comprehensive community-based palliative care space.
One Year After Amazon Bought Whole Foods, Who's Winning the Grocery War?
by Benjamin Rains
Amazon (AMZN) might have forever changed the grocery industry exactly one year ago when the e-commerce giant bought Whole Foods for roughly $14 billion on June 16, 2017. Today, grocery delivery is commonplace across the entire industry.
Should Value Investors Consider CVS Health (CVS) Stock Now?
by Zacks Equity Research
CVS Health (CVS) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
Medical Device Industry Outlook - June 2018
by Zacks Equity Research
The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.
Express Scripts' Inside Rx to Cut Medical Costs for the Aged
by Zacks Equity Research
Express Scripts (ESRX) keeps its commitment towards patient benefit management through subsidiary Inside Rx.
Health Insurance Industry Outlook - May 2018
by Zacks Equity Research
Higher medical enrollment, surging revenues, medical cost management and an increasing share of revenues from complementary services helped results.
Fred's Confirms Sale of Specialty Pharmacy Unit, Stock Up
by Zacks Equity Research
Fred's (FRED) implements its long-standing plans to divest specialty pharmacy segment to CVS Health Corporation.
Fred's (FRED) Q4 Loss Widens Year Over Year, Stock Loses 6%
by Zacks Equity Research
Fred's (FRED) continues to struggle with its front store business. However, the company remains focused on turnaround.
CVS Health (CVS) Beats on Q1 Earnings, Revenues Lag Estimate
by Zacks Equity Research
CVS Health (CVS) witnessed year-over-year growth in Pharmacy Services Segment on the back of growth in pharmacy network and specialty pharmacy volume as well as brand inflation.
Fred's Stock Jumps Over 13% in a Day, 2 Things You Must Note
by Zacks Equity Research
Fred's (FRED) has rescheduled its earnings announcement date.This is solely connected to Fred's plans to divest its specialty pharmacy business.
Why Are Walgreens and CVS Shares Surging Today?
by Ryan McQueeney
Shares of several major pharmaceutical retailers--including Walgreens (WBA) and CVS Health (CVS)--surged in afternoon trading Monday after reports emerged that e-commerce behemoth Amazon (AMZN) has shelved its plan to sell prescription drugs to doctors and hospitals.
Factors Setting the Stage for Fred's (FRED) in Q4 Earnings
by Zacks Equity Research
Fred's (FRED) has been reeling under soft comparable store sales for quite some time now. Let's see if Fred???s strategic initiatives can provide any respite in Q4.
Can Strategic Efforts Aid Fred's to Achieve a Turnaround?
by Zacks Equity Research
Fred's (FRED) focuses on pharmacy organization and expense reduction to achieve turnaround. However, receding comps continue to hurt.
Cigna to Take Over Express Scripts (ESRX) for $67 Billion
by Zacks Equity Research
Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.
Why Is CVS Health Corporation (CVS) Down -9.2% Since its Last Earnings Report?
by Zacks Equity Research
CVS reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Pharmacy Services Aid CVS Health, Aetna Deal an Upside Too
by Zacks Equity Research
CVS Health (CVS) is likely to earn $750 million from near-term synergies after the completion of Aetna acquisition deal.
Walgreens (WBA) May Buy Remaining Stake in AmerisourceBergen
by Zacks Equity Research
Walgreens' (WBA) rumored buyout claim over the remaining stake in AmerisourceBergen comes close on the heels of its rival CVS Health's hefty $69-billion worth acquisition of health insurer, Aetna.